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Introduction

The benefits of fish consumption on cardiovascular disease has
been suggested since the early 1980s in studies that demonstrated
Greenland Eskimo’s low rates of death from coronary heart
disease.1 This was followed by another observational study
that demonstrated the same findings in Japan.2 The proposed
linkage between these two groups of people is their propensity
to consume fish. Since then many studies have examined the
relationship between fish consumption and coronary heart
disease (CHD) mortality rates. Current thinking suggests that
the primary benefit of consuming fish is secondary to the
omega-3 fatty acids found in fish oil.16,17

Omega -3 Fatty Acid Sources and Action

Omega-3 fatty acids are long-chain polyunsaturated fatty
acids (18-22 carbon atoms in chain length) with the first of
double bonds beginning with the third carbon atom. Plants
and marine fish are the two main dietary sources of omega-3
fatty acids found in nature. For the purposes of this article,
we will mainly discuss the role of marine omega-3 fatty acids.
These are generally found in oily fish such as mackerel, lake
trout, herring, sardines, albacore tuna and salmon. There are
two types of marine omega-3 fatty acids: eicosapentaenoic acid
(EPA) & docosahexanoic acid (DHA). In the human body, these
are broken down by the enzymes cyclo-oxygenase and then
lipoxygenase to create eicosanoids.
The exact mechanism of action of omega-3 fatty acids on
CHD remains unknown. However, several ideas have been
postulated. Omega-3 fatty acids have been shown to decrease
serum triglyceride concentrations in a dose dependent
relationship by 25-30%.10 Omega-3 fatty acids have also been
linked to decreased platelet aggregation11,12, 6 as well as the ability
to stabilize the myocardium against ventricular arrhythmia in
animal studies.13, 14, 15, 6

The Evidence

One of the first significant prospective trials done demonstrating
the correlation between consumption of omega-3 fatty acids
and coronary heart disease was done in the Netherlands over a
20 year period. Information about the fish consumption of 852
middle-aged men without coronary heart disease was collected
by a careful dietary history obtained from the participants and
their wives. During 20 years of follow-up 78 men died from
coronary heart disease. An inverse dose-response relation was
observed between fish consumption in 1960 and death from
coronary heart disease during 20 years of follow-up. Mortality
from coronary heart disease was more than 50 % lower among
those who consumed at least 30 grams of fish per day than
among those who did not eat fish. It was concluded that the
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consumption of as little as one or two fish dishes per week may
be of preventive value in relation to coronary heart disease.3
The Netherlands study was shortly followed by the Diet and
Reinfarction Trial (DART) of 1989. This was a randomized
control trial with factorial design performed with the intent
to examine the effect of dietary intervention in secondary
prevention of MI. The major endpoints of the study were total
mortality and ischemic heart disease events (IHD events and
nonfatal MI). Men enrolled in the trial were weighed, measured,
and randomly assigned to receive or not receive dietary advice
on three factors. The first factor was total fat intake. The men
in this arm were designated to reduce fat intake to 30% of total
energy and to increase the polyunsaturated/saturated fat ratio
as much as possible. The next arm was the fish arm. Men were
told to consume at least two weekly portions (200-400 g) of fatty
fish (mackerel, herring, kipper, pilchard, sardine, salmon, and
trout). Men who could not tolerate fish were given the option of
taking three fish oil capsules per day, providing a total of 900 mg
EPA and DHA. The next arm of the study examined fiber intake.
These men were instructed to increase their intake of cereal
fiber to 18 g daily. Weight reduction advice and smoking advice
were given as seen fit to all arms of the study. The results were
surprising. The fish oil arm was shown to have the most CHD
benefit demonstrated by an overall reduction of cardiovascular
disease mortality by 29%. Surprisingly, the overall dietary fat
group did demonstrate a significant decrease in the number of
MIs suffered but did not show any overall benefit in mortality.4
The next large randomized control study to demonstrate a
similar benefit was The Indian Experiment of Infarct Survival
published in 1997. This randomized placebo controlled trial
aimed to test the effect of fish oil and mustard oil supplementation versus placebo on complications and cardiac events
in patients with prior suspected acute myocardial infarction
during a follow-up period of 1 year after symptoms were
first experienced. Participants were randomized to fish oil (6
capsules per day, providing approximately 2 g of omega-3 fatty
acids), mustard seed oil (a source of a-linolenic acid, 2.9 g/d
provided in 20 mL of oil), and placebo (aluminum hydroxide,
100 mg). After one year, total cardiac events were 25% and 28%
in the fish oil and mustard oil groups, respectively, versus 35%
in the placebo group.5, 6
The success of the DART trial and the Indian Experiment
of Infarct Survival trial spawned the Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto miocardico (GISSI)
trial in 1999. This trial was a secondary prevention clinical trial
designed to assess the effects of omega-3 polyunsaturated fatty
acid and vitamin E supplementation on mortality and recurrent
events in patients with recent MI. The study randomized 11,324

patients who had survived a myocardial infarction within the
last 3 months to four arms: omega-3 fatty acid group received
one capsule per day of a highly concentrated product containing
about 850 mg of EPA and DHA, the vitamin-E group received
300 mg/d of synthetic a-tocopherol, the combined treatment
group received both, and the control group received neither.
The GISSI trial was the first demonstration that a pharmaceutical preparation of omega-3 fatty acids in addition to
dietary and other accepted interventions has a favorable effect
on clinical endpoints in post-MI patients. Another unexpected
finding was those taking the omega-3 fatty acids experienced a
20% reduction in overall mortality and a 45% decrease in risk
for sudden cardiac death.7,8
One of the confounders of the above randomized control
trials was that the trials had only included men. As a result,
a retrospective analysis relating coronary artery disease and
fish oil was performed on the cohort of female patients used
for the Nurse’s Health Study. The end point for this study was
incidence of CHD including CHD deaths and nonfatal MI.
Women were divided into 5 categories based on frequency
of fish consumption: <1 serving per month, 1-3 servings
per month, 1 serving per week, 2-4 servings per week, and 5
servings per week. This trial showed a stepwise decrease in all
arms related to more fish consumption in total coronary heart
disease cases, fatal coronary heart disease events, and nonfatal
MI.9 Although this study is convincing, it is also limited by the
inability to control for the fact that people who consume more
fish products may have an inherently healthier lifestyle.

Conclusions

The physician must weigh the risks and benefits of prescribing
fish oil to their patients. It is important to realize the antiplatelet
effects and theoretical ramifications in using omega-3 fatty
acids therapeutically in patients with bleeding tendencies. In
addition, pregnant and nursing woman must be cautioned
against consuming certain fish such as shark, swordfish, golden
bass, and king mackerel that have a higher proportion of
mercury. Studies suggest that prenatal mercury exposure can be
detrimental to neurological development in children.18,19
In 2002, the American Heart Association (AHA) published
guidelines advocating the use of omega-3 fatty acids in patients
with and without documented CHD. In patients without CHD
they recommended eating a variety of (preferably oily) fish at
least twice a week. In patients with CHD they recommended
consuming approximately 1 gram of EPA and DHA daily,
preferably from oily fish. In addition they suggested that in
this patient population fish oil capsules could be considered in
consultation with physicians. In the patients needing triglyceride
lowering the AHA recommended 2 -4 grams of EPA and DHA
daily provided as capsules under a physicians care.6
Omega 3 fatty acids have been shown in epidemiological studies
and randomized control studies to decrease the incidence of

coronary heart disease both in patients with existing coronary
heart disease and prospectively. Although more studies are
needed to examine the exact mechanism of action of omega-3
fatty acids, studies do show a substantial benefit related to the
increase of intake of fish oil, both in capsule form and through
dietary sources. In conclusion, evidence suggests recommending
omega-3 fatty acids to patients at risk for and who have suffered
from cardiovascular heart disease.
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